
    
      This is a Phase II-III, controlled, randomized and double blind for the evaluation of a
      double viral vaccine anti measles and rubella (MR), which is under the development at
      Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in
      human beings. 432 eligible volunteers (11-month-old infants), will be vaccinated and
      monitored for local and systemic adverse events and immunogenicity. The study will last 11
      months in total.
    
  